Marsha L Mason

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 2

Top Topics

Circulating Tumor

Respiratory Syndrome Coronavirus

Antimicrobial Resistance

Top Venues

Science (New York, N.Y.)

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Rebecca Mazahreh, Marsha L Mason, John J Gosink, Devra J Olson, Robert Thurman, Christopher J Hale, Lori Westendorf, Thomas A Pires, Christopher I Leiske, Markus Carlson, Liem T Nguyen, Julia H Cochran, Nicole M Okeley, Roma Yumul, Steven Jin, Ivan J Stone, Disha Sahetya, Albina Nesterova, Sean Allred, Kelly M Hensley, Rachael Hu, Robert T Lawrence, Timothy S Lewis, Sharsti Sandall
SGN-CD228A is an investigational CD228-directed antibody-drug conjugate with potent antitumor activity across a wide spectrum of preclinical solid tumor models. Molecular cancer therapeutics (2023)
Thomas W Linsky, Renan Vergara, Nuria Codina, Jorgen W Nelson, Matthew J Walker, Wen Su, Christopher O Barnes, Tien-Ying Hsiang, Katharina Esser-Nobis, Kevin Yu, Z Beau Reneer, Yixuan J Hou, Tanu Priya, Masaya Mitsumoto, Avery Pong, Uland Y Lau, Marsha L Mason, Jerry Chen, Alex Chen, Tania Berrocal, Hong Peng, Nicole S Clairmont, Javier Castellanos, Yu-Ru Lin, Anna Josephson-Day, Ralph S Baric, Deborah Heydenburg Fuller, Carl D Walkey, Ted M Ross, Ryan Swanson, Pamela J Bjorkman, Michael Gale, Luis M Blancas-Mejia, Hui Ling Yen, Daniel Adriano Silva
De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2. Science (New York, N.Y.) 370 (6521) (2020)